NCT05971043 is a clinical trial in Methamphetamine Abuse, sponsored by Assiut University.

Who is sponsoring NCT05971043?

NCT05971043 is sponsored by Assiut University.

What condition does NCT05971043 study?

NCT05971043 studies Methamphetamine Abuse.

Is NCT05971043 still recruiting?

NCT05971043 is currently status unknown. Last updated 2 August 2023.

Last reviewed 2023-08-02 · How we verify

NCT05971043

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Skin Disease in Methamphetamine Abuse

Status unknown Last updated 2 August 2023

What this trial tests

trial in Methamphetamine Abuse in 500 participants. Status unknown.

Timeline

3 August 2023

Primary endpoint
20 August 2024

20 September 2024

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	3 August 2023
Primary completion	20 August 2024
Estimated completion	20 September 2024

Conditions studied

Methamphetamine Abuse — all drugs for Methamphetamine Abuse →

Sponsor

Assiut University

Who can join

Adults 14 to 75, any sex, with Methamphetamine Abuse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1\. To detect the skin diseases in patients using methamphetamine

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Methamphetamine Abuse

Currently open trials in the same condition.

NCT06721494 — A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamin · Phase 2 · recruiting
NCT06496750 — Ketamine for Methamphetamine Use Disorder · Phase 2 · recruiting
NCT06410196 — Mood and Decision-making in Methamphetamine Use Disorder · NA · recruiting
NCT06233799 — Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder · Phase 3 · recruiting
NCT05700994 — Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM) · NA · active not recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05971043 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 2 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05971043.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing